These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 22356635)

  • 21. Etanercept reduces symptoms and severity of psoriasis after cessation of cyclosporine therapy: results of the SCORE study.
    Micali G; Wilsmann-Theis D; Mallbris L; Gallo G; Marino V; Brault Y; Germain JM
    Acta Derm Venereol; 2015 Jan; 95(1):57-61. PubMed ID: 24682319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. From biologic to biologic to biologic: lessons to learn for erythrodermic and recalcitrant chronic plaque psoriasis.
    Yip L; Harrison S; Foley P
    Australas J Dermatol; 2008 Aug; 49(3):152-5. PubMed ID: 18638223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cessation of cyclosporine therapy by treatment with etanercept in patients with severe psoriasis.
    Yamauchi PS; Lowe NJ
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S135-8. PubMed ID: 16488328
    [No Abstract]   [Full Text] [Related]  

  • 24. Experience with biologics for psoriasis in daily practice: switching is worth a try.
    Lecluse LL; de Groot M; Bos JD; Spuls PI
    Br J Dermatol; 2009 Oct; 161(4):948-51. PubMed ID: 19663876
    [No Abstract]   [Full Text] [Related]  

  • 25. Etanercept: an evolving role in psoriasis and psoriatic arthritis.
    Prodanovich S; Ricotti C; Glick BP; Inverardi L; Leonardi CL; Kerdel F
    Am J Clin Dermatol; 2010; 11 Suppl 1():3-9. PubMed ID: 20586498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-TNF-alpha therapy in childhood pustular psoriasis.
    Pereira TM; Vieira AP; Fernandes JC; Antunes H; Basto AS
    Dermatology; 2006; 213(4):350-2. PubMed ID: 17135745
    [No Abstract]   [Full Text] [Related]  

  • 27. Etanercept combined with methotrexate for high-need psoriasis.
    Driessen RJ; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2008 Aug; 159(2):460-3. PubMed ID: 18547310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic therapies for psoriasis: understanding current and newly emerging therapies.
    Sobell JM; Hallas SJ
    Semin Cutan Med Surg; 2003 Sep; 22(3):187-95. PubMed ID: 14649586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biologicals in the treatment of psoriasis.
    Boker A; Kimball AB; Rolz-Cruz G
    Curr Opin Investig Drugs; 2007 Nov; 8(11):939-46. PubMed ID: 17979028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis.
    van den Reek JM; van Lümig PP; Driessen RJ; van de Kerkhof PC; Seyger MM; Kievit W; de Jong EM
    Br J Dermatol; 2014 Feb; 170(2):415-24. PubMed ID: 24117023
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
    Krueger GG; Langley RG; Finlay AY; Griffiths CE; Woolley JM; Lalla D; Jahreis A
    Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of biologic agents in pediatric psoriasis.
    Marji JS; Marcus R; Moennich J; Mackay-Wiggan J
    J Drugs Dermatol; 2010 Aug; 9(8):975-86. PubMed ID: 20684148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis.
    Strober BE; Crowley JJ; Yamauchi PS; Olds M; Williams DA
    Br J Dermatol; 2011 Sep; 165(3):661-8. PubMed ID: 21574984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Etanercept plus narrowband ultraviolet B phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeks.
    Gambichler T; Tigges C; Scola N; Weber J; Skrygan M; Bechara FG; Altmeyer P; Kreuter A
    Br J Dermatol; 2011 Jun; 164(6):1383-6. PubMed ID: 21466532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial.
    Prinz JC; Fitzgerald O; Boggs RI; Foehl J; Robertson D; Pedersen R; Molta CT; Freundlich B
    J Eur Acad Dermatol Venereol; 2011 May; 25(5):559-64. PubMed ID: 20840349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple squamous cell carcinomas in the setting of psoriasis treated with etanercept: a report of four cases and review of the literature.
    Brewer JD; Hoverson Schott AR; Roenigk RK
    Int J Dermatol; 2011 Dec; 50(12):1555-9. PubMed ID: 22098006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term management of erythrodermic psoriasis with anti-TNF agents.
    Romero-Maté A; García-Donoso C; Martinez-Morán C; Hernández-Núñez A; Borbujo J
    Dermatol Online J; 2010 Jun; 16(6):15. PubMed ID: 20579470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of etanercept in psoriatic patients previously treated with infliximab.
    Pitarch G; Sánchez-Carazo JL; Mahiques L; Oliver V
    Dermatology; 2008; 216(4):312-6. PubMed ID: 18230978
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Etanercept].
    Descamps V
    Ann Dermatol Venereol; 2011 Dec; 138(12):845-7. PubMed ID: 22137625
    [No Abstract]   [Full Text] [Related]  

  • 40. Mechanisms of action of etanercept in psoriasis.
    Tan JK; Aphale A; Malaviya R; Sun Y; Gottlieb AB
    J Investig Dermatol Symp Proc; 2007 May; 12(1):38-45. PubMed ID: 17502868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.